Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy. Valink Therapeutics is a Y Combinator company (Winter 2021). YC-listed status: Active.
- Website
- valinktx.com
- Location
- Boston, MA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- LiliumX — Proprietary bispecific ADC discovery platform using synthetic protein biology, high-throughput screening, and AI to develop next-generation cancer therapeutics. · Other
Links
- Y Combinator profileycombinator